Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study (STARTING-2)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2014 by Samsung Medical Center.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Pharmicell Co., Ltd.
Information provided by (Responsible Party):
Oh Young Bang, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01716481
First received: October 25, 2012
Last updated: May 8, 2014
Last verified: May 2014
History of Changes

October 25, 2012
May 8, 2014
November 2012
November 2015   (final data collection date for primary outcome measure)
Categorical shift in modified Rankin scale (mRS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
Categorical shift in mRS at 90 days after the cell treatment
Same as current
Complete list of historical versions of study NCT01716481 on ClinicalTrials.gov Archive Site
  • Change of National Institutes of Health stroke scale (NIHSS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of NIHSS between pre- and post-treatment 90 days
  • Early improvement of National Institutes of Health stroke scale (NIHSS) [ Time Frame: 14 days after the cell treatment ] [ Designated as safety issue: No ]
    ≥5 points improvement or score of 0-2 on NIHSS score at 14 days after treatment
  • Dichotomized modified Rankin scale (mRS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    mRS ≤2 at 90 days after treatment
  • Change of modified Rankin scale (mRS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of mRS between pre- and post-treatment 90 days
  • Dichotomized modified Barthel index (mBI) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    mBI ≥60 at 90 days after treatment
  • Change of modified Barthel index (mBI) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of mBI between pre- and post-treatment 90 days
  • Change of gross motor function [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of Gross motor function (Motricity index and Fugl-Meyer assessment)between pre- and post-treatment 90 days
  • Change of Fine motor function [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of Fine motor function (Purdue Pegboard test and Box and block test) between pre- and post-treatment 90 days
  • Change of Mobility [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of Mobility (Functional ambulatory category and 10m-Gait speed) between pre- and post-treatment 90 days
  • Change of mini-mental status exam (MMSE) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of MMSE between pre- and post-treatment 90 days
  • Change of quality of life [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of EuroQol 5d (EQ-5D) between pre- and post-treatment 90 days
  • Safety outcome [ Time Frame: During 90 days after the cell treatment ] [ Designated as safety issue: Yes ]
    1. Death: All causes of death
    2. Recurrence: Recurrent stroke or transient ischemic attack

    3. The immediate reaction:

      Allergic reactions (tachycardia, fever, skin eruption, leukocytosis) Local complications (hematoma or local infection at the site of bone marrow aspiration) Vascular obstruction (tachypnea, oliguria, or peripheral vascular insufficiency) Systemic complications (infections,laboratory findings).

    4. Long-term adverse effects possibly related to MSC treatment Tumor formation (physical examination, plain x-ray, f/u MRI at 90 days after treatment), Aberrant connections (newly diagnosed seizure or arrhythmia)
  • Change of NIH stroke scale (NIHSS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of NIHSS between pre- and post-treatment 90 days
  • Early improvement of NIH stroke scale (NIHSS) [ Time Frame: 14 days after the cell treatment ] [ Designated as safety issue: No ]
    ≥5 points improvement or score of 0-2 on NIHSS score at 14 days after treatment
  • Dichotomized modified Rankin scale (mRS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    mRS ≤2 at 90 days after treatment
  • Change of modified Rankin scale (mRS) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of mRS between pre- and post-treatment 90 days
  • Dichotomized modified Barthel index (mBI) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    mBI ≥60 at 90 days after treatment
  • Change of modified Barthel index (mBI) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of mBI between pre- and post-treatment 90 days
  • Change of gross motor function [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of Gross motor function (Motricity index and Fugl-Meyer assessment)between pre- and post-treatment 90 days
  • Change of Fine motor function [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of Fine motor function (Purdue Pegboard test and Box and block test) between pre- and post-treatment 90 days
  • Change of Mobility [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of Mobility (Functional ambulatory category and 10m-Gait speed) between pre- and post-treatment 90 days
  • Change of mini-mental status exam (MMSE) [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of MMSE between pre- and post-treatment 90 days
  • Change of quality of life [ Time Frame: 90 days after the cell treatment ] [ Designated as safety issue: No ]
    Change of EuroQol 5d (EQ-5D) between pre- and post-treatment 90 days
  • Safety outcome [ Time Frame: During 90 days after the cell treatment ] [ Designated as safety issue: Yes ]
    1. Death: All causes of death
    2. Recurrence: Recurrent stroke or transient ischemic attack

    3. The immediate reaction:

      Allergic reactions (tachycardia, fever, skin eruption, leukocytosis) Local complications (hematoma or local infection at the site of bone marrow aspiration) Vascular obstruction (tachypnea, oliguria, or peripheral vascular insufficiency) Systemic complications (infections,laboratory findings).

    4. Long-term adverse effects possibly related to MSC treatment Tumor formation (physical examination, plain x-ray, f/u MRI at 90 days after treatment), Aberrant connections (newly diagnosed seizure or arrhythmia)
Exploration of biomarkers [ Time Frame: During 90 days after the cell treatment ] [ Designated as safety issue: No ]

SDF(stromal cell-derived factor)-1ɑ (chemokine) S100ß (protection and regeneration) HIF(Hypoxia-inducible factor)-1 (preconditioning) Circulating MSCs and MSC-derived microparticles (CD105-CXCR4(C-X-C chemokine receptor type 4)-PS(phosphoserine)) BDNF (Brain-derived neurotrophic factor) levels and it's polymorphism, and VEGF (Vascular endothelial growth factor) levels

Resting-state functional MRI & Diffusion tensor imaging
Not Provided
 
The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study
Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study
The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.
In this study, we will use autologous 'ischemic' serum that obtained at the earliest time point as possible (immediate after randomization) for the purpose of ischemic preconditioning. We have recently conducted preclinical studies on the effects of ischemic preconditioning on the MSC functions. We have evaluated the characteristics of rat MSCs after culture with fetal bovine serum (FBS) or serum obtained from rat stroke model. Compared to FBS, the use of serum obtained from rat stroke model resulted in more rapid expansion of MSCs, which reduces cell preparation time by increase in G2/M phase, decreased cell death/senescence, increased trophic factor secretion, and increased migration capacity.
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Stroke, Ischemic
Other: Mesenchymal stem cell
intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
  • Experimental: Mesenchymal stem cell treatment
    Intervention: Other: Mesenchymal stem cell
  • No Intervention: Standard treatment
Kim SJ, Moon GJ, Chang WH, Kim YH, Bang OY; STARTING-2 (STem cell Application Researches and Trials In NeuroloGy-2) collaborators. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. 2013 Oct 1;14:317. doi: 10.1186/1745-6215-14-317.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
February 2016
November 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Men or women (women must be of non-child bearing potential), age 30-75 yrs.
  2. Have a stroke that is observed within 90 days of the onset of symptoms

  3. Radiologically

    1. Relevant lesions within the middle cerebral artery territory (MCA) as assessed using diffusion-weighted imaging (DWI).
    2. The maximum diameter of the stroke region in any dimension must be ≥15 mm.
    3. Not involving more than a half of the ipsilateral periventricular zone

  4. Clinically (National Institutes of Health stroke scale, NIHSS)

    1. Moderate-to severe persistent neurologic deficit (NIHSS of 6-21 inclusive)
    2. New onset of extremity paresis on the affected side, defined as a score of 2-4 on the NIHSS Motor Arm (item 5) or Leg (item 6) question.
    3. Must be alert or drowsy but easily arousable as defined by score of 0-1 on the NIHSS Level of Consciousness question (item 1).
    4. "Slow recovery" defined as Change in NIHSS ≤1 point/3 days

  5. Willingness

    1. Reasonable likelihood of receiving standard physical, occupational and speech rehabilitation therapy as indicated for the post stroke deficits.
    2. Able to participate in the evaluation process to the point of accurate assessment.
    3. Willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures.
    4. Evidence of a personally signed and dated informed consent document.

Exclusion Criteria:

  1. Presence of significant disability prior to the current stroke. Significant disability is defined as having a pre-stroke modified Rankin score of 2 or more.

  2. Have a stroke that is either

    1. lacunar infarction
    2. Hematologic cause of stroke
    3. Recurrent or progressive stroke within 1 week at the time of screening.
  3. Hematologic disorders or bone marrow suppression.

  4. Have a severe medical illness

    1. Severe heart failure
    2. Severe febrile illness
    3. Hepatic or renal dysfunction
    4. Active cancer
    5. Any evidence of chronic co-morbid condition or unstable acute systemic illnesses which, in the opinion of the investigator, could shorten the subject's survival or limit ability to complete the study.
  5. Presence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis on admission blood tests
  6. Presence of depression that is active and not adequately controlled such that it interfere with major activities of daily living immediately prior to the current stroke.
  7. Presence of dementia prior to the current stroke that is likely to confound clinical evaluation.
  8. Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test or lactating females.
  9. Subjects considered unwilling or unable to comply with the procedures and study visit schedule outlined in the protocol
  10. Subjects unwilling to undergo bone marrow aspiration
Both
30 Years to 75 Years   (Adult, Senior)
No
Contact: Oh Young Bang, MD 82-10-3410-3599 nmboy@unitel.co.kr
Contact: Sang Ae Park, RN 82-10-3410-0934 sa0124.park@samsung.com
Korea, Republic of
 
NCT01716481
2011-10-047
Yes
Not Provided
Not Provided
Oh Young Bang, Samsung Medical Center
Samsung Medical Center
Pharmicell Co., Ltd.
Principal Investigator: Oh Young Bang, MD Samsung Medical Center
Samsung Medical Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP